Takeda Pharmaceutical Co Ltd
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.6% | -10.5% | +7.7% | -3.4% | +12.7% | -17.9% | +12.2% | -4.2% | +15.9% | +43.6% | +18.4% | -4.5% | +6.0% | -10.2% | +3.9% | -1.6% | +6.1% | -7.9% | +23.3% | -11.0% | +6.7% | -3.1% | +11.4% | +3.1% | +9.4% | -12.8% | +10.7% | -1.5% | +6.5% | -5.4% | +15.0% | -2.6% | -2.7% | -7.9% | +5.1% | +0.6% | +9.0% | -8.1% | +9.4% | – | |
| – | +4.3% | -8.9% | -10.1% | +0.8% | +16.8% | -22.1% | +8.7% | -8.2% | +25.1% | +109.2% | +3.7% | -9.6% | +2.9% | -11.2% | -4.1% | +4.9% | +1.4% | +0.1% | -4.8% | +14.3% | +2.0% | +9.6% | -5.0% | +4.3% | +10.0% | -7.8% | +3.7% | +7.0% | +10.4% | +2.1% | -0.1% | +1.9% | +5.7% | -8.3% | +0.7% | -1.2% | +45.5% | +3.3% | -28.8% | – | |
| – | +15.3% | -11.3% | +16.2% | -4.9% | +11.1% | -16.1% | +13.5% | -2.8% | +12.8% | +18.4% | +28.3% | -1.7% | +7.5% | -9.7% | +7.7% | -4.3% | +8.2% | -11.4% | +37.1% | -19.7% | +8.9% | -8.9% | +20.3% | +2.5% | +9.1% | -15.0% | +14.1% | -5.2% | +4.6% | -9.3% | +23.7% | -4.8% | -7.0% | -7.7% | +7.6% | +1.5% | -9.9% | -17.6% | +49.5% | – | |
| – | -4.8% | +23.2% | -14.5% | +4.9% | +2.7% | +8.8% | -18.9% | +10.4% | -2.5% | +80.0% | -16.2% | -2.9% | +8.1% | +13.5% | -23.3% | +10.6% | -0.5% | -3.6% | +8.1% | +7.4% | -2.4% | +11.9% | 0.0% | +7.3% | +13.3% | -7.8% | +1.1% | +13.0% | +1.9% | +4.5% | -14.0% | +4.2% | -3.1% | +26.9% | -33.4% | +12.2% | +10.5% | +11.5% | -15.8% | – | |
| – | – | – | – | +3.8% | -99.1% | +14.9% | +8,841.1% | +2.6% | -99.1% | +19,118.9% | -11.4% | -6.7% | +11.6% | -18.8% | +0.0% | +6.9% | +3.0% | +5.3% | -6.2% | -3.6% | +9.0% | -3.3% | +3.6% | +7.5% | +5.5% | -2.9% | -2.6% | +2.0% | +5.8% | +6.6% | -5.3% | -0.6% | +0.9% | +9.3% | -13.5% | -0.9% | +11.5% | +3.3% | -1.9% | – | |
| – | -1.5% | +31.0% | -61.4% | +105.4% | -5.1% | +43.7% | -37.8% | +7.2% | +0.6% | +122.0% | -2.3% | -7.4% | +5.5% | +11.3% | -32.3% | +23.8% | -10.3% | -16.8% | +25.5% | +2.6% | +6.7% | +12.5% | -6.6% | +12.0% | +3.6% | -9.1% | +2.0% | +31.6% | -16.3% | +7.5% | -2.8% | -8.7% | +10.5% | +13.0% | -28.0% | +23.5% | -29.7% | +6.4% | +23.3% | – | |
| – | +505.4% | -211.2% | – | -79.8% | +123.3% | -191.5% | – | -26.1% | +53.9% | -170.6% | – | +309.9% | +32.3% | -216.1% | – | -71.1% | +196.3% | +5.2% | +65.1% | -60.8% | +19.6% | -101.4% | – | -30.6% | +40.7% | -39.7% | +90.3% | -129.3% | – | -109.6% | – | +10.8% | -63.7% | -211.9% | – | -62.6% | +181.3% | -75.5% | +323.7% | – | |
| – | +2.4% | +6.0% | +59.7% | -39.6% | +12.6% | +35.3% | +61.4% | -38.4% | +144.5% | -70.2% | +593.7% | +15.5% | -17.8% | -98.7% | +8,437.0% | +36.3% | -1.9% | +25.0% | -9.3% | -44.2% | +17.7% | -48.1% | +128.6% | -3.0% | +48.2% | -99.6% | +18,271.7% | -99.3% | +16,485.2% | -99.5% | +18,682.2% | +14.7% | -99.7% | +59.2% | +32,352.5% | -22.4% | +51.4% | -64.7% | +43.6% | – | |
| – | +907.1% | -221.7% | – | -82.5% | +58.0% | -228.7% | – | -28.7% | -28.9% | -338.4% | – | – | – | -570.0% | – | -103.6% | – | +19.2% | +70.4% | -72.4% | +17.5% | -174.9% | – | -58.1% | +63.8% | -55.3% | +182.7% | -170.9% | – | -177.6% | – | -12.6% | -77.9% | -506.3% | – | -81.3% | +383.7% | -139.2% | – | – | |
| – | – | -213.9% | – | -86.7% | -285.6% | – | – | +17.3% | -47.4% | -697.3% | – | – | – | -307.8% | – | -118.4% | – | -481.8% | – | -81.9% | -7.0% | -396.9% | – | -94.4% | -525.8% | – | +171.9% | -205.2% | – | – | – | -34.0% | -90.6% | -263.3% | – | +51.4% | -23.1% | -193.7% | – | – | |
| – | +67.0% | -222.6% | – | -80.6% | +142.9% | -179.3% | – | -38.1% | -22.0% | -246.4% | – | – | -159.8% | – | +4,686.0% | -95.1% | +2,187.8% | +113.4% | -30.1% | -66.6% | +25.7% | -119.7% | – | -41.2% | +92.9% | -73.9% | +187.1% | -153.7% | – | -102.9% | – | -3.4% | -74.2% | -533.8% | – | -109.5% | – | -123.5% | – | – | |
| – | +37.8% | -107.9% | – | -69.5% | +35.7% | -121.1% | – | -21.6% | -6.3% | -22.0% | +133.6% | +9.8% | -24.0% | -67.2% | +490.0% | -41.3% | +51.1% | -31.1% | +124.3% | -44.7% | +10.1% | -50.6% | +181.0% | -22.5% | +27.1% | -45.2% | +83.5% | -44.7% | +27.1% | +0.9% | +49.9% | -2.1% | -49.2% | -6.1% | +142.4% | -28.0% | +44.2% | -65.4% | +113.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.